HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) presented efficacy data for the first time for its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab (anti-CD47…

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab,…

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-GuĂ©rin (BCG)-unresponsive BARCELONA, Spain, Sept. 15, 2024 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) announced today…

Maryland Governor Wes Moore, the late Sheila Jackson-Lee, Dr. Carla Hayden and Jaime Harrison honored at gala ceremony that closes out the 53rd Annual Legislative Conference WASHINGTON, Sept. 14, 2024 /PRNewswire/ — The work of the Congressional Black Caucus (CBC) and the Congressional…

PISCATAWAY, N.J., Sept. 14, 2024 /PRNewswire/ — The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a new era for solid tumor treatment using cell…

WASHINGTON, Sept. 14, 2024 /PRNewswire/ — The Congressional Hispanic Caucus Institute (CHCI) is honored to announce that President Joe Biden and Vice President Kamala D. Harris will offer remarks at this year’s Leadership Conference and Annual Awards Gala as celebrations of Hispanic…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.